I. OVERVIEW OF THE FUNDING OPPORTUNITY

Program Announcement for the Department of Defense

Defense Health Program

Congressionally Directed Medical Research Programs

Defense Medical Research and Development Program

Joint Program Committee 6

Combat Casualty Care Research Program

Battlefield Resuscitation for Immediate Stabilization of Combat Casualties Award

Announcement Type: Initial

Funding Opportunity Number: W81XWH-21-DMRDP-BRISCC

Catalog of Federal Domestic Assistance Number: 12.420 Military Medical Research and Development

SUBMISSION AND REVIEW DATES AND TIMES

- Pre-Application Submission Deadline: 5:00 p.m. Eastern time (ET), January 21, 2021
- Invitation to Submit an Application: February 26, 2021
- Application Submission Deadline: 11:59 p.m. ET, April 7, 2021
- End of Application Verification Period: 5:00 p.m. ET, April 12, 2021
- Peer Review: June 2021
- Programmatic Review: August 2021

This Program Announcement must be read in conjunction with the General Application Instructions, version 601. The General Application Instructions document is available for downloading from the Grants.gov funding opportunity announcement by selecting the “Package” tab, clicking “Preview,” and then selecting “Download Instructions.”
# TABLE OF CONTENTS

**I. OVERVIEW OF THE FUNDING OPPORTUNITY** ....................................................... 1  
**II. DETAILED INFORMATION ABOUT THE FUNDING OPPORTUNITY** ............. 3  
   
   **II.A. Program Description** .......................................................................................... 3  
      **II.A.1. FY21 DMRDP JPC-6/CCCRP Battlefield Resuscitation for Immediate  
         Stabilization of Combat Casualties Focus Areas** .................................................. 3  
   II.B. Award Information .................................................................................................... 4  
   II.C. Eligibility Information .............................................................................................. 7  
      **II.C.1. Eligible Applicants** ..................................................................................... 7  
      **II.C.2. Cost Sharing** .............................................................................................. 8  
      **II.C.3. Other** ......................................................................................................... 8  
   II.D. Application and Submission Information .............................................................. 8  
      **II.D.1. Address to Request Application Package** .................................................... 9  
      **II.D.2. Content and Form of the Application Submission** ....................................... 9  
      **II.D.3. Dun and Bradstreet Data Universal Numbering System (DUNS) Number and  
         System for Award Management (SAM)** .................................................................. 29  
      **II.D.4. Submission Dates and Times** ..................................................................... 30  
      **II.D.5. Funding Restrictions** .................................................................................. 31  
      **II.D.6. Other Submission Requirements** ................................................................. 32  
   II.E. Application Review Information .......................................................................... 32  
      **II.E.1. Criteria** ...................................................................................................... 32  
      **II.E.2. Application Review and Selection Process** ................................................. 36  
      **II.E.3. Integrity and Performance Information** ...................................................... 36  
      **II.E.4. Anticipated Announcement and Federal Award Dates** ................................. 37  
   II.F. Federal Award Administration Information .......................................................... 37  
      **II.F.1. Federal Award Notices** .............................................................................. 37  
      **II.F.2. Administrative and National Policy Requirements** ..................................... 38  
      **II.F.3. Reporting** ................................................................................................... 38  
   II.G. Federal Awarding Agency Contacts ................................................................... 39  
      **II.G.1. CDMRP Help Desk** .................................................................................. 39  
      **II.G.2. Grants.gov Contact Center** ....................................................................... 39  
   II.H. Other Information ................................................................................................... 39  
      **II.H.1. Program Announcement and General Application Instructions Versions** .... 39  
      **II.H.2. Administrative Actions** .............................................................................. 40  
      **II.H.3. Application Submission Checklist** .............................................................. 42  

**APPENDIX I: ACRONYM LIST** .................................................................................. 44  
**APPENDIX II: TECHNOLOGY READINESS LEVELS AND KNOWLEDGE  
READINESS LEVELS** ....................................................................................................... 46  

DoD FY21 DMRDP JPC-6/CCCRP BRISCC Award 2
II. DETAILED INFORMATION ABOUT THE FUNDING OPPORTUNITY

II.A. Program Description

Applications to the Fiscal Year 2021 (FY21) Joint Program Committee 6/Combat Casualty Care Research Program (JPC-6/CCCRP) are being solicited for the Defense Health Agency (DHA) J9, Research and Development Directorate, by the U.S. Army Medical Research Acquisition Activity (USAMRAA) using delegated authority provided by United States Code, Title 10, Section 2358 (10 USC 2358). As directed by the Office of the Assistant Secretary of Defense for Health Affairs (OASD[HA]), the DHA manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The U.S. Army Medical Research and Development Command (USAMRDC) Congressionally Directed Medical Research Programs (CDMRP) provides Defense Medical Research and Development Program (DMRDP) execution management support for DHP core research program areas, including the JPC-6/CCCRP. This Program Announcement and subsequent awards will be managed and executed by CDMRP on behalf of the JPC-6/CCCRP.

The JPC-6/CCCRP is one of six major research program areas within the DHP. The JPC-6/CCCRP is a committee of Department of Defense (DoD) and non-DoD medical and military technical experts in combat casualty care-related program areas. The JPC-6/CCCRP strives to optimize survival and recovery from combat-related or trauma-induced injury in current and future operational scenarios. This is being accomplished through the development of knowledge and materiel products for the acute and early management of combat-related or trauma-induced injury, including point-of-injury, en route, and forward surgical care. Products developed by JPC-6/CCCRP-supported research are applied in-theater and within the clinical facilities of the Military Health System (MHS). These solutions not only minimize the morbidity and mortality of combat-related injuries in Service members, they also are often translatable to the civilian healthcare system.

II.A.1. FY21 DMRDP JPC-6/CCCRP Battlefield Resuscitation for Immediate Stabilization of Combat Casualties Focus Areas

Hemorrhage is the leading cause of preventable deaths among combat casualties occurring before a medical treatment facility is reached. The Battlefield Resuscitation for Immediate Stabilization of Combat Casualties (BRISCC) portfolio seeks to provide materiel and knowledge solutions to enable the immediate stabilization at the point of injury. Current strategic objectives are to provide: (1) technologies to control bleeding in the pre-hospital environment, (2) safer, more effective, and more logistically supportable blood products, and (3) technologies and knowledge sets for improved damage control resuscitation.

The JPC-6/CCCRP has identified the following Focus Areas for funding under the FY21 DMRDP JPC-6/CCCRP BRISCC Award. To meet the intent of the award mechanism, applications MUST specifically address at least one of the BRISCC Award Focus Areas. The BRISCC Award Focus Areas are:
• Novel and/or advanced blood products or volume expanders with oxygen-carrying capacity that offer physiological, logistical, or cost advantages over current products. *Note: Research proposing hemoglobin-based oxygen carrier (HBOC) must demonstrate how nitric oxide-scavenging will be addressed.*

• Tools and techniques to optimize and sustain (more than 12 hours) resuscitation for hemorrhagic shock injuries with an intent to support large-scale multi-domain operations (MDO\(^1\)) and mass casualty-like scenarios.

• Innovative\(^2\) and novel technologies that can stop life-threatening bleeding in the torso region of patients who are delayed in receiving definitive surgical care.

• Innovative and novel devices, drugs, therapies, and clinical practice techniques to treat combat-related and trauma-induced injuries in the pre-hospital setting.

**II.B. Award Information**

The intent of this Program Announcement is to support the early development of high-impact materiel products and new ways, methods, or modifications to existing trauma practice (i.e., knowledge products\(^3\)) for future multi-domain operations (MDO) where evacuation capabilities may be significantly delayed or unavailable. Projects should consider the varied expertise levels of the medical providers and the possible diverse environmental conditions. A focus is on enhancing capabilities at the point of greatest need, including life-saving interventions to be rendered immediately post-injury, during periods of prolonged care in-theater. Medical materiel solutions are encouraged to include characteristics relevant to military use in austere, combat environments. Characteristics and concepts to consider include but are not limited to:

• Low-weight and low-cube: Compared to existing materiel products, the product is a smaller size and weight to aid in portability and storage.

• Low-power, longer shelf life: The product has reduced power usage requirements and longer shelf life than currently available products.

• Modularity and interoperability: The materiel product is compatible with and easily added to existing technologies, equipment, or platforms being used by the military.

• Ruggedization: The materiel product is able to withstand harsh and varied environments such as extreme temperature fluctuations, vibration, and high altitude while maintaining operability and stability.

---

1 Additional information can be found at [https://www.tradoc.army.mil/Portals/14/Documents/MDO/TP525-3-1_30Nov2018.pdf](https://www.tradoc.army.mil/Portals/14/Documents/MDO/TP525-3-1_30Nov2018.pdf).

2 For this Program Announcement, innovation refers to value created through the application of existing and novel ideas and products. The next logical step or continuation of an existing idea or product is not innovative.

3 For this Program Announcement, a knowledge product is information resulting from research with the potential to improve individual or public health ([https://www.rand.org/pubs/research_reports/RR2127.html](https://www.rand.org/pubs/research_reports/RR2127.html)).
- Low-complexity, decision-supported, closed or semi-closed loop feedback or automation: The product is simple to operate, provides decision support to user, and can be partially or fully autonomous. The product can be used by various levels of medical providers with minimal training.

- Affordability: The materiel and knowledge products would result in cost-savings over what is currently available and considers the costs of maintaining and sustaining the product.

The proposed research must be relevant to Service members. It is also expected that outcomes of funded research will benefit Veterans, military beneficiaries, and the American public.

The types of awards made under the Program Announcement will be assistance agreements. An assistance agreement is appropriate when the Federal Government transfers a “thing of value” to a “state, local government,” or “other recipient” to carry out a public purpose of support or stimulation authorized by a law of the United States instead of acquiring property or service for the direct benefit and use of the U.S. Government. An assistance agreement can take the form of a grant or cooperative agreement. The level of involvement on the part of the DoD during project performance is the key factor in determining whether to award a grant or cooperative agreement. If “no substantial involvement” on the part of the funding agency is anticipated, a grant award will be made (31 USC 6304). Conversely, if substantial involvement on the part of the funding agency is anticipated, a cooperative agreement will be made (31 USC 6305), and the award will identify the specific substantial involvement. Substantial involvement may include, but is not limited to, collaboration, participation, or intervention in the research to be performed under the award. The award type, along with the start date, will be determined during the negotiation process.

**Research Scope:** The FY21 DMRDP JPC-6/CCCRP BRISCC Award is structured with three different funding levels based on the scope of the research proposed. It is the responsibility of the Principal Investigator (PI) to select the funding level that is most appropriate for the proposed research project. The Government reserves the right to fund an application at a lower funding level.

- **Funding Level 1:** Innovative, high-risk/high-reward research that is in the early stages of idea development or is an untested theory that addresses an important problem. Preliminary data are not required.

- **Funding Level 2:** Preclinical and clinical research that is supported by substantial preliminary or published data. *Clinical trials are not allowed under this funding opportunity.*

- **Funding Level 3:** Advanced preclinical and clinical research supported by substantial preliminary or published data that require additional financial resources due to maturity of the research proposed. *Clinical trials are not allowed under this funding opportunity.*

The anticipated total costs budgeted for the entire period of performance for an FY21 DMRDP BRISCC Award **Funding Level 1** will not exceed **$800,000**. The anticipated total costs budgeted for the entire period of performance for an FY21 DMRDP BRISCC Award **Funding Level 2** will not exceed **$1.25 million (M)**. The anticipated total costs budgeted for the entire
period of performance for an FY21 DMRDP BRISCC Award Funding Level 3 will not exceed $2.0M. Refer to Section IID.5, Funding Restrictions, for detailed funding information.

Awards will be made no later than September 30, 2022. For additional information refer to Section II.F.1, Federal Award Notices.

The JPC-6/CCCRP expects to allot approximately $4.7M of FY21, $5.5M of FY22, and $6.5M of FY23 DHP RDT&E appropriations to fund approximately 8 to 21 FY21 DMRDP BRISCC Award applications. Funding of applications received is contingent upon the availability of Federal funds for this program as well as the number of applications received, the quality and merit of the applications as evaluated by scientific and programmatic review, and the requirements of the Government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY21 funding opportunity will be funded with FY21 funds, which will expire for use on September 30, 2027; FY22 funds, which will expire for use on September 30, 2028; and FY23 funds, which will expire for use on September 30, 2029. As of the release date of this Program Announcement, the FY21 Defense Appropriations Bill has not been passed and there is no guarantee that any additional funds will be made available to support this program. The funding estimated for this Program Announcement is approximate and subject to realignment. Funding of applications received in response to this Program Announcement is contingent upon the availability of Federal funds for this program.

This Program Announcement may support basic, applied, preclinical, and clinical research involving human subjects and human anatomical substances; however clinical trials are not allowed under this funding opportunity. A clinical trial is defined as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.

Research Involving Human Anatomical Substances, Human Subjects, or Human Cadavers: All DoD-funded research involving new and ongoing research with human anatomical substances, human subjects, or human cadavers must be reviewed and approved by the USAMRDC Office of Research Protections (ORP), Human Research Protection Office (HRPO), prior to research implementation. This administrative review requirement is in addition to the local Institutional Review Board (IRB) or Ethics Committee (EC) review. Local IRB/EC approval at the time of submission is not required. Allow a minimum of 2 to 3 months for HRPO regulatory review and approval processes. Refer to the General Application Instructions, Appendix 1, and the Human Subject Resource Document available on the electronic Biomedical Research Application Portal (eBRAP) “Funding Opportunities & Forms” web page (https://ebrap.org/eBRAP/public/Program.htm) for additional information.

If the proposed research is cooperative (i.e., involving more than one institution), a written plan for single IRB review arrangements must be provided at the time of application submission or award negotiation. The lead institution responsible for developing the master protocol and master consent form should be identified and should be the single point of contact for regulatory submissions and requirements.
Use of DoD or Department of Veterans Affairs (VA) Resources: If the proposed research involves access to active duty military patient populations and/or DoD or VA resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research. Refer to Section II.D.2.b.ii, Full Application Submission Components, for detailed information. Refer to the General Application Instructions, Appendix 1, for additional information.

Recruitment Milestones: For research involving human subject enrollment, the proposal/application must indicate the quarterly enrollment targets across all sites in Attachment 5: Statement of Work. Successful applicants will work with USAMRAA to establish milestones for human subject recruitment. Continued support for the project will be based upon satisfactory progress in meeting the established milestones.

Rigor of Experimental Design: All projects should adhere to accepted standards for rigorous study design and reporting to maximize the reproducibility and translational potential of preclinical research. Core standards are described in Landis, S.C., et al., A call for transparent reporting to optimize the predictive value of preclinical research, Nature 2012, 490:187-191 (www.nature.com/nature/journal/v490/n7419/full/nature11556.html). While these standards were written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in research, and should be applied consistently across basic and translational studies. Projects that include research on animal models are required to submit Attachment 8: Animal Research Plan, as part of the proposal/application package to describe how these standards will be addressed. Applicants should consult the ARRIVE (Animal Research: Reporting In Vivo Experiments) guidelines to ensure relevant aspects of rigorous animal research are adequately planned for, and, ultimately, reported. The ARRIVE guidelines can be found at https://www.elsevier.com/__data/promis_misc/622936arrive_guidelines.pdf.

Research Involving Animals: All DoD-funded research involving new and ongoing research with animals must be reviewed and approved by the USAMRDC ORP Animal Care and Use Review Office (ACURO), in addition to the local Institutional Animal Care and Use Committee (IACUC) of record. IACUC approval at the time of submission is not required. Allow at least 3 to 4 months for ACURO regulatory review and approval processes for animal studies. Refer to the General Application Instructions, Appendix 1, for additional information.

II.C. Eligibility Information

II.C.1. Eligible Applicants

II.C.1.a. Organization: All organizations, including foreign organizations, foreign public entities, and international organizations, are eligible to apply.

Government Agencies Within the United States: Local, state, and Federal Government agencies are eligible to the extent that applications do not overlap with their fully funded internal programs. Such agencies are required to explain how their applications do not overlap with their internal programs.
As applications for this Program Announcement may be submitted by extramural and intramural organizations, these terms are defined below.

**Extramural Organization:** An eligible non-DoD organization. Examples of extramural organizations include academic institutions, biotechnology companies, foundations, Federal Government organization other than the DoD, and research institutes.

**Intramural DoD Organization:** A DoD laboratory, DoD military treatment facility, and/or DoD activity embedded within a civilian medical center. **Intramural Submission:** Application submitted by a DoD organization for an intramural investigator working within a DoD laboratory or military treatment facility or in a DoD activity embedded within a civilian medical center.

USAMRAA makes awards to eligible organizations, not to individuals.

**II.C.1.b. Principal Investigator**

An eligible PI, regardless of ethnicity, nationality, or citizenship status, must be employed by or affiliated with an eligible organization.

The CDMRP encourages all PIs to participate in a digital identifier initiative through Open Researcher and Contributor ID, Inc. (ORCID). Registration for a unique ORCID identifier can be done online at [https://orcid.org/](https://orcid.org/).

**II.C.2. Cost Sharing**

Cost sharing/matching is not an eligibility requirement.

**II.C.3. Other**

Organizations must be able to access .gov and .mil websites in order to fulfill the financial and technical deliverable requirements of the award and submit invoices for payment.

For general information on required qualifications for award recipients, refer to the General Application Instructions, Appendix 3.

Refer to [Section II.H.2, Administrative Actions](#), for a list of administrative actions that may be taken if a pre-application or application does not meet the administrative, eligibility, or ethical requirements defined in this Program Announcement.

**II.D. Application and Submission Information**

*Submission of applications that are essentially identical or propose essentially the same research project to different funding opportunities within the same program and fiscal year is prohibited and will result in administrative withdrawal of the duplicative application(s).*
Extramural Submission:

- Pre-application content and forms must be accessed and submitted at eBRAP.org.
- Full application packages must be accessed and submitted at Grants.gov.

Intramural DoD Submission:

- Pre-application content and forms must be accessed and submitted at eBRAP.org.
- Full application packages must be accessed and submitted at eBRAP.org.

Note: Applications from an intramural DoD organization or from an extramural Federal Government organization may be submitted to Grants.gov through a research foundation.

II.D.1. Address to Request Application Package

eBRAP is a multifunctional web-based system that allows PIs to submit their pre-applications electronically through a secure connection, to view and edit the content of their pre-applications and full applications, to receive communications from the CDMRP, and to submit documentation during award negotiations and period of performance.

Contact information for the CDMRP Help Desk and the Grants.gov Contact Center can be found in Section II.G, Federal Awarding Agency Contacts.

II.D.2. Content and Form of the Application Submission

Submission is a two-step process requiring both pre-application (eBRAP.org) and full application (eBRAP.org or Grants.gov) as indicated below. The submission process should be started early to avoid missing deadlines. There are no grace periods. Full application submission guidelines differ for extramural (Grants.gov) and intramural (eBRAP.org) organizations (refer to Table 1. Full Application Guidelines).

The application title, eBRAP log number, and all information for the PI, Business Official(s), performing organization, and contracting organization must be consistent throughout the entire pre-application and full application submission process. Inconsistencies may delay application processing and limit or negate the ability to view, modify, and verify the application in eBRAP. If any changes need to be made, the applicant should contact the CDMRP Help Desk at help@eBRAP.org or 301-682-5507 prior to the application submission deadline.

II.D.2.a. Step 1: Pre-Application Submission Content

During the pre-application process, eBRAP assigns each submission a unique log number. This unique eBRAP log number is required during the full application submission process.

To begin the pre-application process, first select whether the submitting organization is extramural or intramural, then confirm your selection or cancel. Incorrect selection of extramural or intramural submission type will delay processing.
If an error has been made in the selection of extramural versus intramural and the pre-application submission deadline has passed, the PI or Business Official must contact the CDMRP Help Desk at help@eBRAP.org or 301-682-5507 to request a change in designation.

All pre-application components must be submitted by the PI through eBRAP (https://eBRAP.org/). Because the invitation to submit an application is based on the contents of the pre-application, investigators should not change the title or research objectives after the pre-application is submitted.

The applicant organization and associated PI identified in the pre-application should be the same as those intended for the subsequent application submission. If any changes are necessary after submission of the pre-application, the applicant must contact the CDMRP Help Desk at help@eBRAP.org or 301-682-5507.

A change in PI or organization after submission of the pre-application may be allowed after review of a submitted written appeal (contact the CDMRP Help Desk at help@eBRAP.org or 301-682-5507) and at the discretion of the USAMRAA Grants Officer.

PIs with an ORCID identifier should enter that information in the appropriate field in the “My Profile” tab in the “Account Information” section of eBRAP.

The pre-application consists of the following components, which are organized in eBRAP by separate tabs (refer to the General Application Instructions, Section II.B, for additional information on pre-application submission):

- **Tab 1 – Application Information**

  Submission of application information includes assignment of primary and secondary research classification codes, which may be found at https://ebrap.org/eBRAP/public/Program.htm. Applicants are strongly encouraged to review and confirm the codes prior to making their selection.

- **Tab 2 – Application Contacts**

  Enter contact information for the PI. Enter the organization’s Business Official responsible for sponsored program administration (the “person to be contacted on matters involving this application” in Block 5 of the Grants.gov SF424 Research & Related Form). The Business Official must be either selected from the eBRAP list or invited in order for the pre-application to be submitted.

  Select the performing organization (site at which the PI will perform the proposed work) and the contracting organization (organization submitting on behalf of the PI, which corresponds to Block 5 on the Grants.gov SF424 Research & Related Form), and click on “Add Organizations to this Pre-application.” The organization(s) must be either selected from the eBRAP drop-down list or invited in order for the pre-application to be submitted.

  It is recommended that PIs identify an Alternate Submitter in the event that assistance with pre-application submission is needed.
• **Tab 3 – Collaborators and Key Personnel**

Enter the name, organization, and role of all collaborators and key personnel associated with the application.

FY21 DMRDP JPC-6/CCCRP BRISCC Programmatic Panel members should not be involved in any pre-application or application. For questions related to panel members and pre-applications or applications, refer to Section II.H.2.c, Withdrawal, or contact the CDMRP Help Desk at help@eBRAP.org or 301-682-5507.

• **Tab 4 – Conflicts of Interest**

List all individuals other than collaborators and key personnel who may have a conflict of interest in the review of the application (including those with whom the PI has a personal or professional relationship).

• **Tab 5 – Pre-Application Files**

*Note: Upload documents as individual PDF files unless otherwise noted. eBRAP will not allow a file to be uploaded if the number of pages exceeds the limit specified below.*

○ Preproposal Narrative (three-page limit): The Preproposal Narrative page limit applies to text and non-text elements (e.g., figures, tables, graphs, photographs, diagrams, chemical structures, drawings) used to describe the project. Inclusion of URLs that provide additional information to expand the Preproposal Narrative and could confer an unfair competitive advantage is prohibited and may result in administrative withdrawal of the pre-application.

The Preproposal Narrative should include the following:

– **Research Plan:** Concisely state the ideas and rationale on which the proposed work is based. State the project’s hypotheses, objectives, specific aims, and briefly describe the experimental approach.

– **Personnel:** Briefly state the qualifications of the PI and key personnel to perform the described research project.

– **Impact and Relevance:** State explicitly how the proposed work is innovative (if applicable) and may improve trauma care. Describe the potential impact of this proposal/application to directly or indirectly benefit the public and military Service members.

– **Alignment with Focus Areas:** Identify and explain how the proposed work addresses at least one of the FY21 DMRDP JPC-6/CCCRP BRISCC Award Focus Areas.
○ **Pre-Application Supporting Documentation:** The items to be included as supporting documentation for the pre-application must be uploaded as individual files and are limited to the following:

- **References Cited (one-page limit):** List the references cited (including URLs if available) in the Preproposal Narrative using a standard reference format that includes the full citation (i.e., author[s], year published, reference title, and reference source, including volume, chapter, page numbers, and publisher, as appropriate).

- **List of Abbreviations, Acronyms, and Symbols:** Provide a list of abbreviations, acronyms, and symbols used in the Preproposal Narrative.

- **Key Personnel Biographical Sketches (six-page limit per individual):** All biographical sketches should be uploaded as a single combined file. Biographical sketches should be used to demonstrate background and expertise through education, positions, publications, and previous work accomplished.

- **Budget Summary:** Upload as “BudgetSummary.pdf”. Complete the two-page Pre-Application Budget Summary Form (available for download in eBRAP) as instructed.

- **Quad Chart:** Upload as “QuadChart.pdf”. Complete the Quad Chart template, a one-page PowerPoint file that must be downloaded from the CDMRP eBRAP System at [https://ebrap.org/eBRAP/public/Program.htm](https://ebrap.org/eBRAP/public/Program.htm), and save, using Adobe Acrobat Reader, as a PDF file.

**• Tab 6 – Submit Pre-Application**

This tab must be completed for the pre-application to be accepted and processed.

**Pre-Application Screening**

**• Pre-Application Screening Criteria**

To determine the technical merits of the pre-application and the relevance to the mission of the DHP and the JPC-6/CCCRP, pre-applications will be screened based on the following criteria:

- **Research Plan:** How well the rationale, hypotheses, objectives, specific aims, and experimental approach support the proposed work.

- **Personnel:** To what extent the qualifications of the PI and key personnel are appropriate to perform the proposed research project.

- **Impact and Relevance:** To what extent the study outcomes may improve trauma care. To what extent the proposed study is innovative (if applicable) and will directly or indirectly benefit the public and military Service members.
- **Alignment with Focus Areas:** To what extent the proposed work addresses at least one of the FY21 JPC-6/CCCRP BRISCC Award Focus Areas.

- **Notification of Pre-Application Screening Results**

  Following the pre-application screening, PIs will be notified as to whether or not they are invited to submit applications; however, they will not receive feedback (e.g., a critique of strengths and weaknesses) on their pre-application. The estimated timeframe for notification of invitation to submit an application is indicated in Section I, Overview of the Funding Opportunity. Invitations to submit a full application are based on the Pre-Application Screening Criteria listed above.

**II.D.2.b. Step 2: Full Application Submission Content**

Applications will not be accepted unless notification of invitation has been received.

*The CDMRP cannot make allowances/exceptions to its policies for submission problems encountered by the applicant organization using system-to-system interfaces with Grants.gov.*

Each application submission must include the completed full application package for this Program Announcement. The full application package is submitted by the Authorized Organizational Representative through Grants.gov (https://www.grants.gov) for extramural organizations or through eBRAP (https://ebrap.org/) for intramural organizations. See Table 1 below for more specific guidelines.

**II.D.2.b.i. Full Application Guidelines**

Extramural organizations must submit full applications through Grants.gov. Applicants must create a Grants.gov Workspace for submission, which allows the application components to be completed online and routed through the applicant organization for review prior to submission. Applicants may choose to download and save individual PDF forms rather than filling out webforms in Workspace. A compatible version of Adobe Reader must be used to view, complete, and submit an application package consisting of PDF forms. If more than one person is entering text into an application package, the same version of Adobe Reader software should be used by each person. Check the version number of the Adobe software on each user’s computer to make sure the versions match. Using different versions of Adobe Reader may cause submission and/or save errors – even if each version is individually compatible with Grants.gov. Refer to the General Application Instructions, Section III, and the “Apply For Grants” page of Grants.gov (https://www.grants.gov/web/grants/applicants/apply-for-grants.html) for further information about the Grants.gov Workspace submission process. Submissions of extramural applications through eBRAP may be withdrawn.

*Do not password protect any files of the application package, including the Project Narrative.*
# Table 1. Full Application Submission Guidelines

<table>
<thead>
<tr>
<th>Extramural Submissions</th>
<th>Intramural DoD Submissions</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Application Package Location</strong></td>
<td><strong>Download application package components for W81XWH-21-DMRDP-BRISCC from Grants.gov (<a href="https://www.grants.gov">https://www.grants.gov</a>) and create a Grants.gov Workspace. Workspace allows online completion of the application components and routing of the application package through the applicant organization for review prior to submission.</strong></td>
</tr>
<tr>
<td><strong>Full Application Package Components</strong></td>
<td><strong>Tab 1 – Summary:</strong> Provide a summary of the application information. <strong>Tab 2 – Application Contacts:</strong> This tab will be pre-populated by eBRAP; add Authorized Organizational Representative. <strong>Tab 3 – Full Application Files:</strong> Upload files under each Application Component in eBRAP. Descriptions of each required file can be found under Full Application Submission Components: <strong>Attachments</strong> <strong>Key Personnel</strong> <strong>Budget</strong> <strong>Performance Sites</strong></td>
</tr>
<tr>
<td><strong>SF424 Research &amp; Related Application for Federal Assistance Form:</strong> Refer to the General Application Instructions, Section III.A.1, for detailed information.</td>
<td><strong>Descriptions of each required file can be found under Full Application Submission Components:</strong> <strong>Attachments</strong> <strong>Research &amp; Related Personal Data</strong> <strong>Research &amp; Related Senior/Key Person Profile (Expanded)</strong> <strong>Research &amp; Related Budget</strong> <strong>Project/Performance Site Location(s) Form</strong> <strong>Research &amp; Related Subaward Budget Attachment(s) Form</strong>, if applicable</td>
</tr>
<tr>
<td>Create a Grants.gov Workspace. Add participants (investigators and Business Officials) to Workspace, complete all required forms, and check for errors before submission.</td>
<td>Submit package components to eBRAP (<a href="https://ebrap.org">https://ebrap.org</a>). <strong>Tab 5 – Submit/Request Approval Full Application:</strong> After all components are uploaded and prior to the full application submission deadline, enter your password in the space provided next to “Enter Your Password Here” and press the “Submit Full Application” button. eBRAP will notify your Resource Manager/Comptroller/Task Area Manager or</td>
</tr>
<tr>
<td>Submit a Grants.gov Workspace Package. An application may be submitted through Workspace by clicking the “Sign and Submit” button on the “Manage Workspace” page, under the “Forms” tab. Grants.gov recommends submission of the application package at least</td>
<td></td>
</tr>
</tbody>
</table>
### Extramural Submissions

24-48 hours prior to the close date to allow time to correct any potential technical issues that may disrupt the application submission.

**Note:** If either the Project Narrative or the budget fails eBRAP validation or if the Project Narrative or the budget needs to be modified, an updated Grants.gov application package must be submitted via Grants.gov as a “Changed/Corrected Application” with the previous Grants.gov Tracking ID prior to the application submission deadline. *Do not password protect any files of the application package, including the Project Narrative.*

### Intramural DoD Submissions

equivalent Business Official by email. *Do not password protect any files of the application package, including the Project Narrative.*

### Application Verification Period

The full application package submitted to Grants.gov may be viewed and modified in eBRAP until the end of the application verification period. During the application verification period, the full application package may be modified with the exception of the Project Narrative and Research & Related Budget Form.

After eBRAP has processed the full application, the organizational Resource Manager/Comptroller/Task Area Manager or equivalent Business Official and PI will receive email notification of this status and will be able to view and modify application components in eBRAP. During the application verification period, the full application package may be modified with the exception of the Project Narrative and Research & Related Budget Form. Your Resource Manager/Comptroller/Task Area Manager or equivalent Business Official should log into eBRAP to review and to approve prior to the application verification deadline.

### Further Information

**Tracking a Grants.gov Workspace Package.**

After successfully submitting a Workspace package, a Grants.gov Tracking Number is automatically assigned to the package. The number will be listed on the “Confirmation” page that is generated after submission.

Refer to the General Application Instructions, Section III, for further information regarding Grants.gov requirements.

Refer to the General Application Instructions, Section IV, for further information regarding eBRAP requirements.

The full application package must be submitted using the unique eBRAP log number to avoid delays in application processing.
II.D.2.b.ii. Full Application Submission Components

- Extramural Applications Only

  **SF424 Research & Related Application for Federal Assistance Form:** Refer to the General Application Instructions, Section III.A.1, for detailed information.

- Extramural and Intramural Applications

  **Attachments:**

  *Each attachment to the full application components must be uploaded as an individual file in the format specified and in accordance with the formatting guidelines listed in the General Application Instructions, Appendix 4.*

  For all attachments, ensure that the file names are consistent with the guidance. Attachments will be rejected if the file names are longer than 50 characters or have incorrect file names that contain characters other than the following: A-Z, a-z, 0-9, underscore, hyphen, space, and period. In addition, there are file size limits that may apply in some circumstances. Individual attachments may not exceed 20 MB, and the file size for the entire full application package may not exceed 200 MB.

  ○ **Attachment 1: Project Narrative (15-page limit): Upload as “ProjectNarrative.pdf”**. The page limit of the Project Narrative applies to text and non-text elements (e.g., figures, tables, graphs, photographs, diagrams, chemical structures, drawings) used to describe the project. Inclusion of URLs that provide additional information to expand the Project Narrative and could confer an unfair competitive advantage is prohibited and may result in administrative withdrawal of the application.

  Describe the proposed project in detail using the outline below.

  - **Background:** Describe in detail the scientific rationale for the proposed study. Include a literature review and, if applicable, provide preliminary studies and/or data that support the scientific rationale and led to the development of the research project. The background section should clearly support the choice of study variables and should explain the basis for the study questions and/or study hypotheses. Establish the relevance and applicability of the proposed study and findings to the intent of the mechanism and address at least one of the FY21 JPC-6/CCCRP BRISCC Award Focus Areas. *Note that preliminary studies and data are not required for Funding Level 1 but are required for Funding Levels 2 and 3.*

  - **Objectives/Specific Aims/Hypothesis:** Provide a description of the purpose and objectives of the study with detailed specific aims and hypotheses.
Research Strategy and Feasibility

All proposed research:

- Describe the experimental design, controls, methods, and analyses, and their integration into the project and how they will generate rigorous and reproducible results.

- Define the study variables and describe how they will be measured. Include a description of the choice of model/human subject population (if applicable), appropriate controls, endpoints to be used, and analyses to be performed and how they function to achieve the research objectives and the anticipated outcomes of the study.

- Describe the statistical plan as appropriate for the proposed research, including the sample size projection/power analysis, blinding, randomization, and data analysis plan.

- Identify and describe potential problem areas in the proposed approach and alternative methods and approaches that will be employed to mitigate any risks that are identified.

- Applications that include research on animal models are also required to submit Attachment 8: Animal Research Plan.

For research involving human subjects:

- Describe the population(s) of interest and how they relate to the research objectives.

- Describe the methods that will be used to recruit a sample of human subjects from the accessible population (e.g., convenience, simple random, stratified random).

- Describe the human subject-to-group assignment process (e.g., randomization, block randomization, stratified randomization, age-matched controls, alternating group, or other procedures), if applicable. Explain the specific actions to accomplish the group assignment (e.g., computer assignment, use of table of random numbers).

- Specify the approximate number of human subjects that will be enrolled. If multiple study sites are involved, state the approximate number to be enrolled at each site. Include a complete power analysis to demonstrate that the sample size is appropriate to meet the objectives of the study. If a subpopulation of a recruited sample population will be used for analysis, complete a statistical analysis to ensure appropriate power can be achieved within the subpopulation study.
- **Personnel:** Describe how the composition, background, expertise, levels of effort and record of success of the research/study team personnel (e.g., study coordinator, statistician, etc.) are appropriate to ensure success of the proposed research.

○ **Attachment 2: Supporting Documentation:** Combine and upload as a single file named “Support.pdf”. Start each document on a new page. If documents are scanned to PDF, the lowest resolution (100 to 150 dpi) should be used. The Supporting Documentation attachment should not include additional information such as figures, tables, graphs, photographs, diagrams, chemical structures, or drawings. These items should be included in the Project Narrative.

_There are no page limits for any of these components unless otherwise noted. Include only those components described below; inclusion of items not requested or viewed as an extension of the Project Narrative will result in the removal of those items or may result in administrative withdrawal of the application._

- References Cited: List the references cited (including URLs, if available) in the Project Narrative using a standard reference format that includes the full citation (i.e., author[s], year published, title of reference, source of reference, volume, chapter, page numbers, and publisher, as appropriate).

- List of Abbreviations, Acronyms, and Symbols: Provide a list of abbreviations, acronyms, and symbols.

- Facilities, Existing Equipment, and Other Resources: Describe the facilities and equipment available for performance of the proposed project and any additional facilities or equipment proposed for acquisition at no cost to the award. Indicate whether or not Government-furnished facilities or equipment are proposed for use. If so, reference should be made to the original or present Government award under which the facilities or equipment items are now accountable. There is no form for this information.

- Publications and/or Patents: Include a list of relevant publication URLs and/or patent abstracts. If articles are not publicly available, then copies of up to five published manuscripts may be included in Attachment 2. Extra items will not be reviewed.

- Letters of Organizational Support (two-page limit per letter): Provide a letter (or letters, if applicable) signed by the Department Chair or appropriate organization official, confirming the laboratory space, equipment, and other resources available for the project. Letters of support not requested in the Program Announcement, such as those from members of Congress, do not impact application review or funding decisions.

- Letters of Collaboration (if applicable) (two-page limit per letter): Provide a signed letter from each collaborating individual or organization that will demonstrate that the PI has the support or resources necessary for the proposed work. If an investigator at an intramural organization is named as a collaborator on an application submitted through an extramural organization, the application must include a letter from the
collaborator’s Commander or Commanding Officer at the intramural organization that authorizes the collaborator’s involvement.

  
  ▪ Intellectual and Material Property Plan (if applicable): Provide a plan for resolving intellectual and material property issues among participating organizations.

  ▪ Commercialization Strategy (if applicable): Describe the commercialization plan. The plan should include intellectual property, market size, financial analysis, strengths and weaknesses, barriers to the market, competitors, and management team. Discuss the significance of this development effort, when it can be anticipated, and the potential commercial use for the technology being developed.

- Data and Research Resources Sharing Plan: Describe how data and resources generated during the performance of the project will be shared with the research community. Refer to the General Application Instructions, Appendix 2, Section K, for more information about the CDMRP expectations for making data and research resources publicly available.

- Use of DoD Resources (if applicable): Provide a letter of support signed by the lowest-ranking person with approval authority confirming access to active duty military populations and/or DoD resources or databases.

- Use of VA Resources (if applicable): Provide a letter of support from the VA Facility Director(s) or individual designated by the VA Facility Director(s), such as the Associate Chief of Staff for Research and Development (ACOS/R&D) or Clinical Service Chief, confirming access to VA patients, resources, and/or VA research space. For VA PIs, if the VA non-profit corporation is not identified as the applicant institution for administering the funds, include a letter from the VA ACOS/R&D confirming this arrangement and identifying the institution that will administer the funds associated with the proposed research.

  ○ Attachment 3: Technical Abstract (one-page limit): Upload as “TechAbs.pdf”. The technical abstract is used by all reviewers. Abstracts of all funded research projects will be posted publicly. **Do not include proprietary or confidential information.** Use only characters available on a standard QWERTY keyboard. Spell out all Greek letters, other non-English letters, and symbols. Graphics are not allowed.

  The structured technical abstract should be clear and concise and, at a minimum, provide the following information:

  – **Background:** Present the ideas and reasoning behind the proposed work.

  – **Objective/Hypothesis:** State the objective to be reached/hypothesis to be tested. Provide evidence or rationale that supports the objective/hypothesis.
- **Specific Aims:** State the specific aims of the study.

- **Study Design:** Briefly describe the study design including appropriate controls. For studies enrolling human subjects, describe the population and enrollment targets. For animal studies, include a description of the animal model.

- **Impact:** Identify the FY21 JPC-6/CCCRP BRISCC Award Focus Area(s) to be addressed and briefly describe how the proposed research will impact trauma care.

○ **Attachment 4: Lay Abstract (one-page limit): Upload as “LayAbs.pdf”**. The lay abstract is used by all reviewers. Abstracts of all funded research projects will be posted publicly. *Do not include proprietary or confidential information*. Use only characters available on a standard QWERTY keyboard. Spell out all Greek letters, other non-English letters, and symbols. Graphics are not allowed.

Lay abstracts should be written using the outline below. Do not duplicate the technical abstract.

- Describe the objectives and rationale for the research in a manner that will be readily understood by readers without a science or medical background.

- Identify the FY21 JPC-6/CCCRP BRISCC Award Focus Area(s) to be addressed.

- Describe the potential research and clinical applications, benefits, and risks.

- Describe the projected timeline to achieve the expected patient-related outcome.

- Describe how the proposed project will benefit Service members and/or the public.

○ **Attachment 5: Statement of Work (five-page limit): Upload as “SOW.pdf”**. The suggested Statement of Work (SOW) format and examples specific to different types of research projects are available on the eBRAP “Funding Opportunities & Forms” web page (https://ebrap.org/eBRAP/public/Program.htm). Recommended strategies for assembling the SOW can be found at https://ebrap.org/eBRAP/public/Program.htm.

For the FY21 DMRDP BRISCC Award, refer to either the “Suggested SOW Strategy Clinical Research” or “Suggested SOW Strategy Generic Research,” whichever format is most appropriate for the proposed effort and use the blank SOW format titled “Suggested SOW Format.” The SOW must be in PDF format prior to attaching.

The SOW should include a list of major tasks that support the proposed specific aims, followed by a series of subtasks outlined related to the major tasks and milestones within the period of performance. The SOW should describe only the work for which funding is being requested by this application and, as applicable, should also:

- Include the name(s) of the key personnel and contact information for each study site/subaward site.
– Indicate the number (and type, if applicable) of research subjects (animal or human) and/or human anatomical samples projected or required for each task and at each site. Refer to the General Application Instructions, Appendix 1, for additional information regarding regulatory requirements.

– For studies with prospective accrual of human subjects, indicate quarterly enrollment targets.

– Identify cell line(s) and commercial or organizational source(s) to be used.

○ Attachment 6: Impact and Military Benefit Statement (two-page limit): Upload as “Impact.pdf”. Explain the proposed research project’s potential impact and military benefit as follows:

  – Innovation (if applicable\(^4\)): Describe how the proposed research is innovative.

  – Short-Term Impact: Describe the anticipated short-term outcome(s) that will have the potential to optimize survival and recovery from combat-related or trauma-induced injury in austere environments and when access to definitive medical care is delayed or unavailable.

  – Long-Term Impact: Describe the anticipated research outcomes or long-term vision that will impact the development of medical solutions for Service members and the public. Describe how the proposed materiel or knowledge product represents an improvement to currently available pharmacologic agents, devices, or clinical guidance (as applicable).

  – Military Benefit: Clearly articulate how the proposed research can optimize survival and recovery during future MDO where evacuation capabilities may be significantly delayed or unavailable.

  – Public Purpose: Concisely describe how this research can benefit the general public.

  – Challenges: Describe potential issues that might limit the impact of the proposed research and strategies that may be employed to overcome those issues.

○ Attachment 7: Transition Plan (if applicable; required for all studies requesting Level 2 and Level 3 funding; three-page limit): Upload as “Transition.pdf”. Provide information on the methods and strategies proposed to move the anticipated research outcomes to the next phase of research or delivery to the military or civilian market/clinical practice after successful completion of the award. Applicants are encouraged to work with their organization’s Technology Transfer Office (or equivalent) to develop the transition plan. PIs are encouraged to explore developing relationships with industry and/or other funding agencies to facilitate moving the product into the next

\(^4\) Refer to the FY21 JPC-6/CCCRP BRISCC Award Focus Areas for items requesting innovative technology capabilities or management.
phase of development. The post-award transition plan should include the components listed below.

- Using Appendix II as a guide, describe the maturity of the product, and provide the current and projected research technology or knowledge readiness level (as appropriate) at the end of the period of performance.

- Details of the funding strategy that will be used to bring the outcomes to the next level (e.g., specific potential industry partners, specific funding opportunities to be pursued).

- A description of collaborations and other resources that will be used to provide continuity of development.

- For Knowledge Products, a description of collaborations and other resources that will be used to provide continuity of development, including proposed development or modification of clinical practice guidelines and recommendations, provider training materials, patient brochures, and other clinical support tools, scientific journal publications, models, simulations, and applications.

- A brief schedule and milestones for transitioning the intervention to the next phase of development (i.e., next-phase clinical trials, commercialization, delivery to the military or civilian market, incorporation into clinical practice, and/or approval by the U.S. Food and Drug Administration [FDA]).

- Ownership rights/access to the intellectual property necessary for the development and/or commercialization of products or technologies supported with this award and the Government’s ability to access such products or technologies in the future.

- A risk analysis for cost, schedule, manufacturability, and sustainability, if applicable.

  o **Attachment 8: Animal Research Plan (if applicable; required for all studies utilizing animals; five-page limit per animal study):** Upload as “AnimRschPln.pdf”.

When the proposed study involves animals, the applicant is required to submit a summary describing the animal research that will be conducted. Applicants should not submit a verbatim replica of the protocol(s) to be submitted to the IACUC as the Animal Research Plan. The Animal Research Plan should address the following points for each proposed animal study:

- Briefly describe the research objective(s) of the animal study. Explain how and why the animal species, strain, and model(s) being used can address the scientific objectives and, where appropriate, the study’s relevance to human biology.

- Summarize the procedures to be conducted. Describe how the study will be controlled.
Describe the randomization and blinding procedures for the study, and any other measures to be taken to minimize the effects of subjective bias during animal treatment and assessment of results. If randomization and/or blinding will not be utilized, provide justification.

Provide a sample size estimate for each study arm and the method by which it was derived, including power analysis calculations.

Describe how data will be handled, including rules for stopping data collection, criteria for inclusion and exclusion of data, how outliers will be defined and handled, statistical methods for data analysis, and identification of the primary endpoint(s).

Describe how data will be reported and how it will be assured that the documentation will support a regulatory filing with the FDA, if applicable.

Attachment 9: Data Management (if applicable; required for all studies recruiting human subjects; no page limit): Upload as “Data_Manage.pdf”. The Data Management attachment should include the components listed below.

Data Management: Describe all methods used for data collection, including the following:

- Identifiers: Describe the unique identifiers or specific code system to be used to identify human subjects, if applicable.

- Confidentiality:
  - Explain measures taken to protect the privacy of human subjects and maintain confidentiality of study data. Strategies to protect the privacy and confidentiality of study records, particularly those containing identifying information, should be addressed.
  - Address who will have access to study records, data, and specimens, including an acknowledgment that representatives of the DoD are eligible to review study records.
  - Address requirements for reporting sensitive information to state or local authorities.

- Data capture, verification, and disposition: Describe how data will be captured and verified. Describe where data (both electronic and hard copy) will be stored, who will keep the data, how the data will be stored, the process for locking the database at study completion, and the length of time data will be stored. Describe the proposed database, how it will be developed and validated, and its capability to safeguard and maintain the integrity of the data. Describe the database lock process. For FDA-regulated studies, compliance with 21 CFR 11 and appropriate data standards (such as those established by the Clinical Data Interchange Standards Consortium) are required.
- **Data reporting**: Describe how data will be reported and how it will be assured that the documentation will support a regulatory filing with the FDA, if applicable.

- **Sharing study results**: In cases where the human subject could possibly benefit medically or otherwise from the information, explain whether or not the results of screening and/or study participation will be shared with human subjects or their primary care provider, including results from any screening or diagnostic tests performed as part of the study.

- **Laboratory Evaluations**:
  
  - **Specimens to be collected, schedule, and amount**: All specimens that will be collected for study purposes must be clearly stated. The collection schedule and amount of material collected must also be clearly described.

  - **Evaluations to be made**: Describe all evaluations that will be made for study purposes. Explain how the results of laboratory evaluations will be used to meet the objectives of the study (or to monitor safety of human subjects).

  - **Storage**: Describe specimen storage, including location of storage, how long specimens will be stored, any special conditions required, labeling, and specimen disposition. Outline the plan to store specimens for future use, including considerations for informed consent and providing human subjects with an opportunity to decline participation in the study.

  - **Laboratories performing evaluations and special precautions**: Identify the laboratory performing each evaluation, the applicable quality standard, and any special precautions that should be taken in handling the samples. Special precautions that should be taken by the human subject before, during, or after the laboratory procedure should be clearly defined. If transport of samples is required, describe provisions for ensuring proper storage during transport.

  - **Attachment 10: Human Subject Recruitment and Safety Procedures (if applicable; required for all studies recruiting human subjects; no page limit)**: Upload as “HumSubProc.pdf”. The Human Subject Recruitment and Safety Procedures attachment should include the components listed below.

    **Applicants and collaborating organizations may not use, employ, or subcontract for the use of any human participants, including the use of human anatomical substances, human data, and/or human cadavers until applicable regulatory documents are reviewed and approved by the USAMRDC ORP to ensure that DoD regulations have been met.**

- **Study Population**: Describe the target population (to whom the study findings will be generalized) and the nature, approximate number, and pertinent demographic characteristics of the accessible population at the study site (population from whom the sample will be recruited/drawn). Provide a table of anticipated enrollment counts.
at each study site. Demonstrate that the research team has access to the proposed study population at each site. Furthermore, discuss past efforts in recruiting human subjects from the target population for previous clinical studies (if applicable). Address any potential barriers to accrual and plans for addressing unanticipated delays, including a mitigation plan for slow or low enrollment. Identify ongoing clinical research or trials that may compete for the same patient population and how they may impact enrollment progress. Provide justification related to the scientific goals of the proposed study for limiting inclusion of any group by age, race, ethnicity, or sex/gender. For clinical studies proposing to include military personnel, refer to the regulatory requirements in General Application Instructions, Appendix 1, for additional information.

- **Inclusion/Exclusion Criteria:** List the inclusion and exclusion criteria for the proposed clinical study. Inclusion/exclusion criteria should take into consideration the specific risk profile of the studies to be conducted and the standard of care for that patient population. Provide detailed justification for exclusions.

- **Women and Minorities in the Study:** Consistent with the Belmont Report, “Ethical Principles and Guidelines for the Protection of Human Subjects,” and Congressional legislation, special attention is given to inclusion of women and/or minorities in studies funded or supported by the USAMRDC. This policy is intended to promote equity both in assuming the burdens and in receiving the benefits of human subjects research. Describe the strategy for the inclusion of women and minorities in the clinical trial appropriate to the objectives of the study, including a description of the composition of the proposed study population in terms of sex/gender, race, and ethnicity, and an accompanying rationale for the selection of subjects. Provide an anticipated enrollment table(s) with the proposed enrollment distributed on the basis of sex/gender, race, and ethnicity. The suggested Inclusion Enrollment Report format is a one-page fillable PDF form, which can be downloaded from eBRAP at [https://ebrap.org/eBRAP/public/Program.htm](https://ebrap.org/eBRAP/public/Program.htm).

- **Description of the Recruitment and Retention Process:** Explain methods for identification of potential human subjects (e.g., medical record review, obtaining sampling lists, healthcare provider identification).
  
  - Describe the recruitment and retention process in detail. Address who will identify potential human subjects, who will recruit them, and what methods will be used to recruit and retain them.
  
  - Include a detailed description of and justification for the compensation plan if the human subjects will be compensated for participation in the study.
  
  - Describe the recruitment and advertisement materials. The recruitment materials should not be coercive or offer undue inducements and should accurately reflect the study.
Description of the Informed Consent Process: Specifically describe the plan for obtaining informed consent from human subjects.

- Identify who is responsible for explaining the study, answering questions, and obtaining informed consent. Include a plan for ensuring that human subjects’ questions will be addressed during the consent process and throughout the study.

- Include information regarding the timing and location of the consent process.

- Address issues relevant to the mental capacity of the potential human subject (e.g., altered capacity due to brain injury, stress/life situations, or human subject age or administration of any mind-altering substances such as tranquilizers, conscious sedation or anesthesia), if applicable.

- Address how privacy and time for decision making will be provided and whether or not the potential human subject will be allowed to discuss the study with anyone before making a decision.

- Consider the need for obtaining ongoing consent or for re-assessing capacity over the course of a long-term study and describe any relevant procedures to assure continued consent.

- Describe the plan for the consent of the individual’s Legally Authorized Representative (LAR) to be obtained prior to the human subject’s participation in the study. State law defines who may act as the LAR. The local IRB of record should be consulted for guidance regarding who can serve as LAR for research at the study site. Note: In compliance with 10 USC 980 ([https://www.gpo.gov/fdsys/pkg/USCODE-2011-title10/pdf/USCODE-2011-title10-subtitleA-partII-chap49-sec980.pdf](https://www.gpo.gov/fdsys/pkg/USCODE-2011-title10/pdf/USCODE-2011-title10-subtitleA-partII-chap49-sec980.pdf)), the PI must describe a clear intent to benefit for human subjects who cannot give their own consent to participate in the proposed clinical research. If applicable, refer to the General Application Instructions, Appendix 1, for more information.

- **Assent.** If minors or other populations that cannot provide informed consent are included in the proposed clinical research, a plan to obtain assent (agreement) from those with capacity to provide it, or a justification for a waiver of assent, should be provided. PIs should consult with their local IRB to identify the conditions necessary for obtaining assent.

Screening Procedures: List and describe any evaluations (e.g., laboratory procedures, history, or physical examination) that are required to determine eligibility/suitability for study participation and the diagnostic criteria for entry. Note that some screening procedures may require a separate consent or a two-stage consent process. Informed consent must be obtained prior to initiation of any procedures for the purpose of determining eligibility.
- **Risks/Benefits Assessment:**
  
  **Foreseeable risks:** Clearly identify all study risks, including potential safety concerns and adverse events. Study risks include any risks that the human subject is exposed to as a result of participation in the clinical research. Consider psychological, legal, social, and economic risks as well as physical risks. If the risks are unknown, this should be stated. If applicable, any potential risk to the study personnel should be identified.

  **Risk management and emergency response:**
  
  - Describe how safety surveillance and reporting to the IRB and FDA (if applicable) will be managed and conducted.
  
  - Describe all safety measures to minimize and/or eliminate risks to human subjects and study personnel or to manage unpreventable risks. Include safeguards and planned responses such as dose reduction or stopping criteria based on toxicity grading scales or other predetermined alert values.
  
  - Discuss the overall plan for provision of emergency care or treatment for an adverse event for study-related injuries, including who will be responsible for the cost of such care.
  
  - Address any special precautions to be taken by the human subjects before, during, and after the study (e.g., medication washout periods, dietary restrictions, hydration, fasting, pregnancy prevention).
  
  - Describe any special care (e.g., wound dressing assistance, transportation due to side effects of study impairing ability to drive) or equipment (e.g., thermometers, telemedicine equipment) needed for human subjects enrolled in the study.
  
  - If the IRB determines that a trial presents greater than minimal risk to human subjects, the DoD requires an independent research monitor with expertise consistent with the nature of risk(s) identified within the research protocol. If applicable, refer to the General Application Instructions, Appendix 1, Section B (Research Monitor Requirement), for more information on study reporting authorities and responsibilities of the research monitor.

  **Potential benefits:** Describe known and potential benefits of the study to the human subjects who will participate in the study. Articulate the importance of the knowledge to be gained as a result of the proposed research. Discuss why the potential risks to human subjects are reasonable in relation to the anticipated benefits to the human subjects and others that may be expected to result.

  - **Attachment 11:** Representations, if applicable (extramural submissions only): Upload as “RequiredReps.pdf”. All extramural applicants must complete and submit the Required Representations template available on eBRAP (https://ebrap.org/eBRAP/).
public/Program.htm). For more information, see the General Application Instructions, Appendix 5, Section B, Representations.

- **Attachment 12: Suggested Collaborating DoD Military Facility Budget Format, if applicable:** Upload as “MFBudget.pdf”. If a military facility (Military Health System facility, research laboratory, medical treatment facility, dental treatment facility, or a DoD activity embedded with a civilian medical center) will be a collaborator in performance of the project, complete a separate budget, using “Suggested Collaborating DoD Military Facility Budget Format,” available for download on the eBRAP “Funding Opportunities & Forms” web page [https://ebrap.org/eBRAP/public/Program.htm](https://ebrap.org/eBRAP/public/Program.htm), including a budget justification, for each military facility as instructed. The costs per year should be included on the Grants.gov Research & Related Budget Form under subaward costs. Refer to the General Application Instructions, Section III.A.8, for detailed information.

- **Extramural and Intramural Applications**

To evaluate compliance with Title IX of the Education Amendments of 1972 (20 USC A§1681 et seq.), the DoD is collecting certain demographic and career information to be able to assess the success rates of women who are proposed for key roles in applications in science, technology, engineering, and/or mathematics (STEM) disciplines. To enable this assessment, each application must include the following forms completed as indicated.

**Research & Related Personal Data:** For extramural submissions (via Grants.gov), refer to the General Application Instructions, Section III.A.3, and for intramural submissions (via eBRAP), refer to the General Application Instructions, Section IV.A.2, for detailed information.

**Research & Related Senior/Key Person Profile (Expanded):** For extramural submissions (via Grants.gov), refer to the General Application Instructions, Section III.A.4, and for intramural submissions (via eBRAP), refer to the General Application Instructions, Section IV.A.3, for detailed information.

- **PI Biographical Sketch (six-page limit):** Upload as “Biosketch_LastName.pdf”. The suggested biographical sketch format is available on the “Funding Opportunities & Forms” web page [https://ebrap.org/eBRAP/public/Program.htm](https://ebrap.org/eBRAP/public/Program.htm) in eBRAP. The National Institutes of Health Biographical Sketch may also be used. All biographical sketches should be submitted in uneditable PDF format.

- **PI Previous/Current/Pending Support (no page limit):** Upload as “Support_LastName.pdf”.

For extramural submissions, refer to the General Application Instructions, Section III.A.4 for detailed information.

For intramural submissions, refer to the General Application Instructions, Section IV.A.3, for detailed information.
× Key Personnel Biographical Sketches (six-page limit each): Upload as “Biosketch_LastName.pdf”.

× Key Personnel Previous/Current/Pending Support (no page limit): Upload as “Support_LastName.pdf”.

Research & Related Budget: For extramural submissions (via Grants.gov), refer to the General Application Instructions, Section III.A.5, and for intramural submissions (via eBRAP), refer to the General Application Instructions, Section IV.A.4, for detailed information.

Budget Justification (no page limit): Upload as “BudgetJustification.pdf”. The budget justification for the entire period of performance must be uploaded to the Research & Related Budget after completion of the budget for Period 1.

Project/Performance Site Location(s) Form: For extramural submissions (via Grants.gov), refer to the General Application Instructions, Section III.A.6, and for intramural submissions (via eBRAP), refer to the General Application Instructions, Section IV.A.5, for detailed information.

• Extramural Applications Only

Research & Related Subaward Budget Attachment(s) Form (if applicable): Refer to the General Application Instructions, Section III.A.7, for detailed information.

× Extramural Subaward: Complete the Research & Related Subaward Budget Form through Grants.gov. (Refer to the General Application Instructions, Section III.A.7, for detailed information.) Verify subaward budget(s) and budget justification forms are present in eBRAP during the application verification period. If these components are missing, upload them to eBRAP before the end of the application verification period.

× Intramural DoD Collaborator(s): Complete the “Suggested Collaborating DoD Military Facility Budget Format” and upload to Grants.gov attachment form as Attachment 12. (Refer to the General Application Instructions, Section IV.A.4, for detailed information.) Each Intramural DoD Collaborator should include costs per year on the Grants.gov Research & Related Budget Form under subaward costs.

II.D.3. Dun and Bradstreet Data Universal Numbering System (DUNS) Number and System for Award Management (SAM)

Applicant organizations and all sub-recipient organizations must have a DUNS number to submit applications to Grants.gov. The applicant organization must also be registered in the Entity Management functional area of the SAM with an “Active” status to submit applications through the Grants.gov portal. Verify the status of the applicant organization’s Entity registration in SAM well in advance of the application submission deadline. Allow several weeks to complete the entire SAM registration process. If an applicant has not fully complied with the requirements at the time the Federal awarding agency is ready to make a Federal award, the Federal awarding agency may determine that the applicant is not qualified to receive a Federal award and use that
determination as a basis for making a Federal award to another applicant. Refer to the General Application Instructions, Section III, for further information regarding Grants.gov requirements.

**Announcement of Transition to SAM-Generated Unique Entity Identifier (UEI):** Through April 2022, a transition from DUNS to the SAM-generated UEI will occur. Refer to the General Application Instructions, Section III.1, DUNS Number, for more information on the transition and timing.

**II.D.4. Submission Dates and Times**

All submission dates and times are indicated in Section I, Overview of the Funding Opportunity. Pre-application and application submissions are required. The pre-application and application submission process should be started early to avoid missing deadlines. There are no grace periods. Failure to meet either of these deadlines will result in submission rejection.

**Applicant Verification of Full Application Submission in eBRAP**

**For Both Extramural and Intramural Applicants:** eBRAP allows an organization’s representatives and PIs to view and modify the full application submissions associated with them. Following retrieval and processing of the full application, eBRAP will notify the organizational representatives and PI by email to log into eBRAP to review, modify, and verify the full application submission. eBRAP will validate full application files against the specific Program Announcement requirements, and discrepancies will be noted in an email to the PI and in the “Full Application Files” tab in eBRAP. eBRAP does not confirm the accuracy of file content. Application viewing, modification, and verification in eBRAP are strongly recommended, but not required. It is the applicant’s responsibility to review all application components and ensure proper ordering as specified in the Program Announcement. **If either the Project Narrative or the budget fails eBRAP validation or needs to be modified, an updated full application package must be submitted prior to the application submission deadline.** The Project Narrative and Research & Related Budget Form cannot be changed after the application submission deadline. Other application components may be changed until the end of the application verification period. Verify that subaward budget(s) and budget justification forms are present in eBRAP during the application verification period. If these components are missing, upload them to eBRAP before the end of the application verification period. After the end of the application verification period, the full application cannot be modified.

**Extramural Submission:** The full application package submitted to Grants.gov may be viewed and modified in eBRAP until the end of the application verification period. During the application verification period, the full application package, with the exception of the Project Narrative and Budget Form, may be modified.

**Intramural DoD Submission:** After eBRAP has processed the full application, the organizational Resource Manager/Comptroller/Task Area Manager or equivalent Business Official and PI will receive email notification of the status and will be able to view and modify application components in eBRAP. During the application verification period, the full application package, with the exception of the Project Narrative and Budget Form, may be modified. The Resource Manager/Comptroller/Task Area Manager or equivalent Business
Official should log into eBRAP to review and to approve the application package prior to the application verification deadline.

**For All Submissions:** Verify that subaward budget(s) with budget justification are present in eBRAP during the application verification period. If these components are missing, upload them to eBRAP before the end of the application verification period.

II.D.5. Funding Restrictions

*The requested funding level should be aligned with the scope of the research proposed and the funding level descriptions. The Government reserves the right to fund an application at a lower funding level.*

**Funding Level 1:**

The maximum period of performance is 3 years.

- The anticipated total costs (direct and indirect) budgeted for the entire period of performance will not exceed **$800,000**. Indirect costs are to be budgeted in accordance with the organization’s negotiated rate. No budget will be approved by the Government exceeding **$800,000** total costs or using an indirect rate exceeding the organization’s negotiated rate.

**Funding Level 2:**

- The maximum period of performance is 3 years.

- The allowable range of total costs (direct and indirect) budgeted for the entire period of performance is **$1.25M**. Indirect costs are to be budgeted in accordance with the organization’s negotiated rate. No budget will be approved by the Government exceeding **$1.25M** total costs or using an indirect rate exceeding the organization’s negotiated rate.

**Funding Level 3:**

- The maximum period of performance is 3 years.

- The allowable range of total costs (direct and indirect) budgeted for the entire period of performance is **$2.0M**. Indirect costs are to be budgeted in accordance with the organization’s negotiated rate. No budget will be approved by the Government exceeding **$2.0M** total costs or using an indirect rate exceeding the organization’s negotiated rate.

**For All Funding Levels:**

- All direct and indirect costs of any subaward or contract must be included in the total direct costs of the primary award.

- The applicant may request the entire maximum funding amount for a project that may have a period of performance less than the maximum 3 years.

- The maximum period of performance is 3 years.
All direct and indirect costs of any subaward or contract must be included in the total direct costs of the primary award.

For this award mechanism, direct costs must be requested for:

- Travel costs for the PI to present project information or disseminate project results at a DoD-sponsored meeting (e.g., progress review meeting or Military Health System Research Symposium during the period of performance in year 2. For planning purposes, it should be assumed that the meeting will be held in the Central Florida Region. These travel costs are in addition to those allowed for annual scientific/technical meetings.

May be requested for (not all inclusive):

- Travel in support of multidisciplinary collaborations.

- Costs for one investigator to travel to one scientific/technical meeting per year in addition to the required meeting described above. The intent of travel costs to scientific/technical meeting is to present project information or disseminate project results from the FY21 DMRDP JPC-6/CCCRP BRISCC Award.

Must not be requested for:

- Clinical trial costs

For extramural awards with an intragovernmental component, direct transfer of funds from an extramural award recipient to a DoD or other Federal agency is not allowed except under very limited circumstances. Funding to intramural DoD and other Federal agencies will be managed through a direct funds transfer. Intramural applicants are responsible for coordinating through their agency’s procedures the use of contractual or assistance funding awards or other appropriate agreements to support extramural collaborators.

Refer to the General Application Instructions, Section III.A.5, for budget regulations and instructions for the Research & Related Budget. For Federal agencies or organizations collaborating with Federal agencies, budget restrictions apply as are noted in the General Application Instructions, Section III.A.5.

II.D.6. Other Submission Requirements

Refer to the General Application Instructions, Appendix 4, for detailed formatting guidelines.

II.E. Application Review Information

II.E.1. Criteria

II.E.1.a. Peer Review

To determine technical merit, all applications will be evaluated according to the following scored criteria, which are listed in decreasing order of importance:
• **Research Strategy and Feasibility**
  
  ○ If applicable, how well the literature review and preliminary studies and data support the scientific rationale of the research project and led to the development of the research project. *Preliminary studies and data are not required for Funding Level 1 but are required for Funding Levels 2 and 3.*

  ○ How relevant and applicable the proposed research and findings are to at least one of the FY21 DMRDP JPC-6/CCCRP BRISCC Award Focus Areas.

  ○ How well the objectives/specific aims and hypotheses are described.

  ○ How consistent the methods and procedures are with a sound research design and how they will generate rigorous and reproducible results.

  ○ How well the study is designed to achieve the research objectives and the anticipated outcomes of the study, including the choice of model/human subject population (as applicable), appropriate controls, endpoints to be used, and analyses to be performed.

  ○ How well the proposal/application acknowledges potential problems and addresses alternative approaches.

  ○ Whether the research can be completed within the proposed period of performance.

  ○ For clinical research involving human subjects:
    - How well the proposal/application describes the population(s) of interest, demonstrates access to these populations, and has a viable plan for recruitment, consent, screening, and retention of appropriate subjects.
    - How well the stated inclusion/exclusion criteria take into consideration the specific risk profile of the studies to be conducted and the standard of care for that patient population.
    - Whether the strategy for the inclusion of women and minorities is appropriate to the objectives of the study.
    - Whether the distribution of the proposed enrollment on the basis of sex/gender, race, and/or ethnicity is appropriate for the proposed research.

• **Impact**
  
  ○ If applicable, to what degree the proposed research is innovative.

  ○ To what extent the short-term outcome(s) of the proposed research has the potential to optimize survival and recovery from combat-related or trauma-induced injury in austere environments and when access to definitive medical care is delayed or unavailable.
○ To what extent the anticipated research outcomes or long-term vision of the proposed research may impact the development of medical solutions for Service members and the public.

○ If applicable, to what degree the proposed materiel or knowledge product represents an improvement to currently available pharmacologic agents, devices, or clinical guidance (as applicable).

- **Personnel**
  ○ How the composition of the research or study team (e.g., study coordinator, statistician) is appropriate.
  ○ How the levels of effort by the PI and other key personnel are appropriate to ensure success of the proposed research.
  ○ How the study team’s background, expertise, and record(s) of accomplishment demonstrate their ability to accomplish the proposed work.

- **Ethical Considerations (for studies recruiting human subjects)**
  ○ How the level of risk to human subjects is minimized, and how the safety monitoring and reporting plan is appropriate for the level of risk.
  ○ To what degree privacy issues are appropriately considered.
  ○ To what degree the process for seeking informed consent is appropriate.

- **Statistical Plan**
  ○ To what degree the statistical plan, including sample size projections/power analysis, blinding, randomization, and data analysis plan are adequate for the study and all proposed correlative studies.
  ○ If applicable, whether the statistical plan compensates for the use of a subpopulation of a recruited sample population to ensure appropriate power can be achieved within the subpopulation study.

- **Transition Plan (if applicable)**
  ○ Whether the funding strategy described to move the anticipated research outcome(s) to the next phase of research or delivery to the military or civilian market/clinical practice is appropriate.
  ○ Whether appropriate collaborations and other resources for providing continuity of development are established and/or well described.
○ How the schedule and milestones for transitioning the outcome(s) to the next phase of development (i.e., next-phase clinical trials, commercialization, delivery to the military or civilian market, incorporation into clinical practice, and/or approval by the FDA) are appropriate.

○ If applicable, how well the potential risk analysis for cost, schedule, manufacturability, and sustainability is developed.

○ How well the application identifies intellectual property ownership, describes any appropriate intellectual and material property plan among participating organizations (if applicable), and addresses any impact of intellectual property issues on product development and subsequent Government rights and ability to access such products or technologies supported by this Program Announcement.

In addition, the following unscored criteria will also contribute to the overall evaluation of the application:

• **Budget**
  ○ Whether the total costs exceed the allowable total costs as published in the Program Announcement.
  ○ Whether the budget is appropriate for the proposed research.

• **Environment**
  ○ To what degree the scientific environment and the accessibility of institutional/organizational resources support the proposed research requirements (including collaborative arrangements).
  ○ How the quality and extent of institutional/organizational support are appropriate for the proposed project.

• **Application Presentation**
  ○ To what extent the writing, clarity, and presentation of the application components influence the review.

II.E.1.b. **Programmatic Review**

To make funding recommendations and select the application(s) that, individually or collectively, will best achieve the program objectives, the following criteria are used by programmatic reviewers:

• Ratings and evaluations of the peer reviewers

• Relevance to the mission of the DHP and JPC-6/CCCRP, as evidenced by the following:
  ○ Adherence to the intent of the award mechanism
II.E.2. Application Review and Selection Process

All applications are evaluated by scientists, clinicians, and consumers in a two-tier review process. The first tier is peer review, the evaluation of applications against established criteria to determine technical merit, where each application is assessed for its own merit, independent of other applications. The second tier is programmatic review, a comparison-based process in which applications with high scientific and technical merit are further evaluated for programmatic relevance. Final recommendations for funding are made to the Commanding General, USAMRDC, on behalf of the DHA and the OASD(HA). The highest-scoring applications from the first tier of review are not automatically recommended for funding. Funding recommendations depend on various factors as described in Section II.E.1.b, Programmatic Review. Additional information about the two-tier process used by the CDMRP can be found at https://cdmrp.army.mil/about/2tierRevProcess. An information paper describing the funding recommendations and review process for the award mechanisms for the DMRDP will be provided to the PI and posted on the CDMRP website.

All CDMRP review processes are conducted confidentially to maintain the integrity of the merit-based selection process. Panel members sign a statement declaring that application and evaluation information will not be disclosed outside the panel. Violations of confidentiality can result in the dissolving of a panel(s) and other corrective actions. In addition, personnel at the applicant or collaborating organizations are prohibited from contacting persons involved in the review and approval process to gain protected evaluation information or to influence the evaluation process. Violations of these prohibitions will result in the administrative withdrawal of the organization’s application. Violations by panel members or applicants that compromise the confidentiality of the review and approval process may also result in suspension or debarment from Federal awards. Furthermore, the unauthorized disclosure of confidential information of one party to another third party is a crime in accordance with 18 USC 1905.

II.E.3. Integrity and Performance Information

Prior to making an assistance agreement award where the Federal share is expected to exceed the simplified acquisition threshold, as defined in 2 CFR 200.88, over the period of performance, the Federal awarding agency is required to review and consider any information about the applicant that is available in the Federal Awardee Performance and Integrity Information System (FAPIIS).

An applicant organization may review FAPIIS, accessible through SAM, and submit comments to FAPIIS on any information about the organization that a Federal awarding agency previously entered and is currently available in FAPIIS.

The Federal awarding agency will consider any comments by the applicant, in addition to other information in the designated integrity and performance system, in making a judgment about the
applicant’s integrity, business ethics, and record of performance under Federal awards when determining a recipient’s qualification prior to award, according to the qualification standards of the Department of Defense Grant and Agreement Regulations (DoDGARs), Section 22.415.

II.E.4. Anticipated Announcement and Federal Award Dates

All application review dates and times are indicated in Section I, Overview of the Funding Opportunity.

Each PI and organization will receive email notification of posting of the funding recommendation in eBRAP. Each PI will receive a peer review summary statement on the strengths and weaknesses of the application.

II.F. Federal Award Administration Information

II.F.1. Federal Award Notices

Awards supported with FY21, FY22, and FY23 funds are anticipated to be made no later than September 30, 2023. Refer to the General Application Instructions, Appendix 2, for additional award administration information.

After email notification of application review results through eBRAP, and if selected for funding, a representative from USAMRAA will contact the Business Official authorized to negotiate on behalf of the PI’s organization.

**Pre-Award Costs:** An institution of higher education, hospital, or other non-profit organization may, at its own risk and without the Government’s prior approval, incur obligations and expenditures to cover costs up to 90 days before the beginning date of the initial budget period of a new award. Refer to the General Application Instructions, Section III.A.5.

*Only an appointed USAMRAA Grants Officer may obligate the Government to the expenditure of funds.* No commitment on the part of the Government should be inferred from discussions with any other individual. **The award document signed by the Grants Officer is the official authorizing document.**

**Federal Government Organizations:** Funding made to Federal Government organizations (to include intramural DoD organizations) will be executed through the Military Interdepartmental Purchase Request (MIPR) or Funding Authorization Document (FAD) process. Transfer of funds is contingent upon appropriate safety and administrative approvals. Intramural applicants and collaborators are reminded to coordinate receipt and commitment of funds through their respective Resource Manager/Task Area Manager/Comptroller or equivalent Business Official.

II.F.1.a. PI Changes and Award Transfers

Unless otherwise restricted, changes in PI will be allowed at the discretion of the Grants Officer, provided the intent of the award mechanism is met.
An organizational transfer of an award will not be allowed in the last year of the (original) period of performance or any extension thereof.

Refer to the General Application Instructions, Appendix 2, Section B, for general information on organization or PI changes.

**II.F.2. Administrative and National Policy Requirements**

Applicable requirements in the DoDGARs found in 32 CFR, Chapter I, Subchapter C, and 2 CFR, Chapter XI, apply to grants and cooperative agreements resulting from this Program Announcement.

Refer to the General Application Instructions, Appendix 2, for general information regarding administrative requirements.

Refer to the General Application Instructions, Appendix 5, for general information regarding national policy requirements.

Refer to full text of the latest [DoD R&D General Terms and Conditions](https://ebrap.org/eBRAP/public/Program.htm); the [USAMRAA General Research Terms and Conditions with Institutions of Higher Education, Hospitals, and Non-Profit Organizations: Addendum to the DoD R&D General Terms and Conditions](https://ebrap.org/eBRAP/public/Program.htm); and the [USAMRAA General Research Terms and Conditions with For-Profit Organizations](https://ebrap.org/eBRAP/public/Program.htm) for further information.

**II.F.3. Reporting**

Refer to the General Application Instructions, Appendix 2, Section A, for general information on reporting requirements. *If there are technical reporting requirement delinquencies for any existing USAMRAA-sponsored awards at the applicant organization, no new awards will be issued to the applicant organization until all delinquent reports have been submitted.*

Annual progress reports as well as a final progress report and quad charts, will be required.

Quarterly progress reports and quad charts may be required.

The Award Terms and Conditions will specify if more frequent reporting is required.

Award Expiration Transition Plan: An Award Expiration Transition Plan must be submitted with the final progress report. Use the one-page template “Award Expiration Transition Plan,” available on the eBRAP “Funding Opportunities & Forms” web page (https://ebrap.org/eBRAP/public/Program.htm) under the “Progress Report Formats” section. The Award Expiration Transition Plan must outline if and how the research supported by this award will progress and must include source(s) of funding, either known or pending.

Inclusion Enrollment Reporting Requirement *(only required for clinical research studies)*: Enrollment on the basis of sex/gender, race, and/or ethnicity will be required with each annual and final technical report. The suggested Inclusion Enrollment Report format is available on the “Funding Opportunities & Forms” web page (https://ebrap.org/eBRAP/public/Program.htm) in eBRAP.
Awards resulting from this Program Announcement will incorporate additional reporting requirements related to recipient integrity and performance matters. Recipient organizations that have Federal contract, grant, and cooperative agreement awards with a cumulative total value greater than $10M are required to provide information to FAPIIS about certain civil, criminal, and administrative proceedings that reached final disposition within the most recent 5-year period and that were connected with performance of a Federal award. Recipients are required to disclose, semiannually, information about criminal, civil, and administrative proceedings as specified in the applicable Representations (see General Application Instructions, Appendix 5, Section B).

II.G. Federal Awarding Agency Contacts

II.G.1. CDMRP Help Desk

Questions related to Program Announcement content or submission requirements as well as questions related to the pre-application or intramural application submission through eBRAP should be directed to the CDMRP Help Desk, which is available Monday through Friday from 8:00 a.m. to 5:00 p.m. ET. Response times may vary depending upon the volume of inquiries.

Phone: 301-682-5507

Email: help@eBRAP.org

II.G.2. Grants.gov Contact Center

Questions related to extramural application submission through Grants.gov portal should be directed to the Grants.gov Contact Center, which is available 24 hours a day, 7 days a week (closed on U.S. Federal holidays). Note that the CDMRP Help Desk is unable to provide technical assistance with Grants.gov submission.

Phone: 800-518-4726; International 1-606-545-5035

Email: support@grants.gov

Sign up on Grants.gov for “send me change notification emails” by following the link on the “Synopsis” page for the Program Announcement or by responding to the prompt provided by Grants.gov when first downloading the Grants.gov application package. If the Grants.gov application package is updated or changed, the original version of the application package may not be accepted by Grants.gov.

II.H. Other Information

II.H.1. Program Announcement and General Application Instructions Versions

Questions related to this Program Announcement should refer to the Program name, the Program Announcement name, and the Program Announcement version code 601a. The Program Announcement numeric version code will match the General Application Instructions version code 601.
II.H.2. Administrative Actions

After receipt of pre-applications or applications, the following administrative actions may occur:

II.H.2.a. Rejection

The following will result in administrative rejection of the pre-application:

- PreproposaI Narrative exceeds page limit.
- PreproposaI Narrative is missing.

The following will result in administrative rejection of the application:

- Submission of an application for which a letter of invitation was not received.
- Project Narrative exceeds page limit.
- Project Narrative is missing.
- Budget is missing.

*For proposals/applications involving animal research:*

- Attachment 8, Animal Research Plan, is missing.

*For proposals/applications recruiting human subjects:*

- Attachment 9, Data Management, is missing.
- Attachment 10, Human Subject Recruitment and Safety Procedures, is missing.

II.H.2.b. Modification

- Pages exceeding the specific limits will be removed prior to review for all documents other than the PreproposaI Narrative and Project Narrative.
- Documents not requested will be removed.

II.H.2.c. Withdrawal

The following may result in administrative withdrawal of the pre-application or application:

- An FY21 DMRDP JPC-6/CCCRP BRISCC Award Programmatic Panel member is named as being involved in the research proposed or is found to have assisted in the pre-application or application processes including, but not limited to, concept design, application development, budget preparation, and the development of any supporting documentation. A list of the FY21 DMRDP JPC-6/CCCRP BRISCC Award Programmatic Panel members can be found at [https://cdmrp.army.mil/dmrdp/panels/21jpc_6](https://cdmrp.army.mil/dmrdp/panels/21jpc_6).
• The application fails to conform to this Program Announcement description.

• Inclusion of URLs, with the exception of links in References Cited and Publication and/or Patent Abstract sections.

• Page size is larger than 8.5 inches x 11.0 inches (approximately 21.59 cm x 27.94 cm).

• To preserve the integrity of its peer and programmatic review processes, the CDMRP discourages inclusion of any employee of its review contractors having any role in the preparation, research or other duties for submitted applications. For FY21, the identities of the peer review contractor and the programmatic review contractor may be found at the CDMRP website (https://cdmrp.army.mil/about/2tierRevProcess). Applications that include names of personnel from either of these companies may be administratively withdrawn.

• Personnel from applicant or collaborating organizations are found to have contacted persons involved in the review or approval process to gain protected evaluation information or to influence the evaluation process.

• Applications from extramural organizations, including non-DoD Federal agencies, received through eBRAP may be withdrawn.

• Applications submitted by an intramural DoD organization may be withdrawn if the intramural organization cannot coordinate the use of contractual, assistance, or other appropriate agreements to provide funds to extramural collaborators.

• Submission of the same research project to different funding opportunities within the same program and fiscal year.

• The invited application proposes a different research project than that described in the pre-application.

• A clinical trial is proposed.

II.H.2.d. Withhold

Applications that appear to involve research misconduct will be administratively withheld from further consideration pending organizational investigation. The organization will be required to provide the findings of the investigation to the USAMRAA Grants Officer for a determination of the final disposition of the application.
II.H.3. Application Submission Checklist

<table>
<thead>
<tr>
<th>Application Components</th>
<th>Action</th>
<th>Completed</th>
</tr>
</thead>
<tbody>
<tr>
<td>SF424 Research &amp; Related Application for Federal Assistance (extramural submissions only)</td>
<td>Complete form as instructed</td>
<td></td>
</tr>
<tr>
<td>Summary (Tab 1) and Application Contacts (Tab 2) (intramural submissions only)</td>
<td>Complete tabs as instructed</td>
<td></td>
</tr>
<tr>
<td>Attachments</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Project Narrative: Upload as Attachment 1 with file name “ProjectNarrative.pdf”</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Supporting Documentation: Upload as Attachment 2 with file name “Support.pdf”</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Technical Abstract: Upload as Attachment 3 with file name “TechAbs.pdf”</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lay Abstract: Upload as Attachment 4 with file name “LayAbs.pdf”</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Statement of Work: Upload as Attachment 5 with file name “SOW.pdf”</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Impact and Military Benefit Statement: Upload as Attachment 6 with file name “Impact.pdf”</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Transition Plan: Upload as Attachment 7 with file name “Transition.pdf” (if applicable; required for all studies requesting Level 2 and Level 3 funding)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Animal Research Plan: Upload as Attachment 8 with file name “AnimRschPln.pdf” (if applicable; required for all studies utilizing animals)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Data Management: Upload as Attachment 9 with file name “Data_Manage.pdf” (if applicable; required for all studies recruiting human subjects)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Human Subject Recruitment and Safety Procedures: Upload as Attachment 10 with file name “HumSubProc.pdf” (if applicable; required for all studies recruiting human subjects)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Representations (extramural submissions only): Upload as Attachment 11 with file name “RequiredReps.pdf” if applicable</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Application Components</td>
<td>Action</td>
<td>Completed</td>
</tr>
<tr>
<td>-------------------------------------------------------------</td>
<td>------------------------------------------------------------------------------------------</td>
<td>-----------</td>
</tr>
<tr>
<td></td>
<td>Suggested Collaborating DoD Military Facility Budget Format: Upload as Attachment 12 with file name “MFBudget.pdf” if applicable</td>
<td></td>
</tr>
<tr>
<td>Research &amp; Related Personal Data</td>
<td>Complete form as instructed</td>
<td></td>
</tr>
<tr>
<td>Research &amp; Related Senior/Key Person Profile (Expanded)</td>
<td>Attach PI Biographical Sketch (Biosketch_LastName.pdf) to the appropriate field</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Attach PI Previous/Current/Pending Support (Support_LastName.pdf) to the appropriate field</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Attach Biographical Sketch (Biosketch_LastName.pdf) for each senior/key person to the appropriate field</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Attach Previous/Current/Pending (Support_LastName.pdf) for each senior/key person to the appropriate field</td>
<td></td>
</tr>
<tr>
<td>Research &amp; Related Budget (extramural submissions only)</td>
<td>Complete as instructed. Attach Budget Justification (BudgetJustification.pdf) to the appropriate field</td>
<td></td>
</tr>
<tr>
<td>Budget (intramural submissions only)</td>
<td>Suggested DoD Military Budget Format, including justification</td>
<td></td>
</tr>
<tr>
<td>Project/Performance Site Location(s) Form</td>
<td>Complete form as instructed</td>
<td></td>
</tr>
<tr>
<td>Research &amp; Related Subaward Budget Attachment(s) Form, if applicable</td>
<td>Complete form as instructed</td>
<td></td>
</tr>
</tbody>
</table>
**APPENDIX I: ACRONYM LIST**

<table>
<thead>
<tr>
<th>Acronym</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACOS/R&amp;D</td>
<td>Associate Chief of Staff for Research and Development</td>
</tr>
<tr>
<td>ACURO</td>
<td>Animal Care and Use Review Office</td>
</tr>
<tr>
<td>BRISCC</td>
<td>Battlefield Resuscitation for Immediate Stabilization of Combat Casualties</td>
</tr>
<tr>
<td>CCCR P</td>
<td>Combat Casualty Care Research Program</td>
</tr>
<tr>
<td>CDMRP</td>
<td>Congressionally Directed Medical Research Programs</td>
</tr>
<tr>
<td>CFR</td>
<td>Code of Federal Regulations</td>
</tr>
<tr>
<td>DHA</td>
<td>Defense Health Agency</td>
</tr>
<tr>
<td>DHP</td>
<td>Defense Health Program</td>
</tr>
<tr>
<td>DMRDP</td>
<td>Defense Medical Research and Development Program</td>
</tr>
<tr>
<td>DoD</td>
<td>Department of Defense</td>
</tr>
<tr>
<td>DoDGARs</td>
<td>Department of Defense Grant and Agreement Regulations</td>
</tr>
<tr>
<td>DUNS</td>
<td>Data Universal Numbering System</td>
</tr>
<tr>
<td>eBRAP</td>
<td>Electronic Biomedical Research Application Portal</td>
</tr>
<tr>
<td>EC</td>
<td>Ethics Committee</td>
</tr>
<tr>
<td>ET</td>
<td>Eastern Time</td>
</tr>
<tr>
<td>FAD</td>
<td>Funding Authorization Document</td>
</tr>
<tr>
<td>FAPIIS</td>
<td>Federal Awardee Performance and Integrity Information System</td>
</tr>
<tr>
<td>FDA</td>
<td>U.S. Food and Drug Administration</td>
</tr>
<tr>
<td>FY</td>
<td>Fiscal Year</td>
</tr>
<tr>
<td>HBOC</td>
<td>Hemoglobin-based Oxygen Carrier</td>
</tr>
<tr>
<td>HRPO</td>
<td>Human Research Protection Office</td>
</tr>
<tr>
<td>IACUC</td>
<td>Institutional Animal Care and Use Committee</td>
</tr>
<tr>
<td>IRB</td>
<td>Institutional Review Board</td>
</tr>
<tr>
<td>JPC</td>
<td>Joint Program Committee</td>
</tr>
<tr>
<td>KP</td>
<td>Knowledge Product</td>
</tr>
<tr>
<td>KRL</td>
<td>Knowledge Readiness Level</td>
</tr>
<tr>
<td>LAR</td>
<td>Legally Authorized Representative</td>
</tr>
<tr>
<td>M</td>
<td>Million</td>
</tr>
<tr>
<td>MDO</td>
<td>Multi-Domain Operations</td>
</tr>
<tr>
<td>MIPR</td>
<td>Military Interdepartmental Purchase Request</td>
</tr>
<tr>
<td>OASD(HA)</td>
<td>Office of the Assistant Secretary of Defense for Health Affairs</td>
</tr>
<tr>
<td>ORCID</td>
<td>Open Researcher and Contributor ID, Inc.</td>
</tr>
<tr>
<td>ORP</td>
<td>Office of Research Protections</td>
</tr>
<tr>
<td>PI</td>
<td>Principal Investigator</td>
</tr>
<tr>
<td>RDT&amp;E</td>
<td>Research, Development, Test, and Evaluation</td>
</tr>
<tr>
<td>ROC</td>
<td>Roles of Care</td>
</tr>
<tr>
<td>SAM</td>
<td>System for Award Management</td>
</tr>
<tr>
<td>SOW</td>
<td>Statement of Work</td>
</tr>
</tbody>
</table>
STEM Science, Technology, Engineering, and/or Mathematics
TRA Technology Readiness Assessment
TRL Technology Readiness Level
UEI Unique Entity Identifier
URL Uniform Resource Locator
USAMRAA U.S. Army Medical Research Acquisition Activity
USAMRDC U.S. Army Medical Research and Development Command
USC United States Code
VA Department of Veterans Affairs
APPENDIX II: TECHNOLOGY READINESS LEVELS AND KNOWLEDGE READINESS LEVELS

Technology Readiness Levels (TRLs): TRLs are used to categorize the product maturity of materiel solutions. The DoD Technology Readiness Assessment (TRA) Deskbook is a reference for systematic assessment of technical maturity of relevant materiel solutions. For biomedical applications, biomedical TRL definitions and descriptions have been developed that account for regulatory context for technology maturity and intended context of use. Information on biomedical TRLs can be found in Appendix E of the DoD TRA Deskbook (July 2009, https://apps.dtic.mil/docs/citations/ADA524200).

Knowledge Readiness Levels (KRLs): The scientific maturity of knowledge products resulting from biomedical research are not assessed in the same manner as materiel solutions. At the request of the U.S. Army Medical Research and Development Command, the Rand Corporation developed and released a framework to assess the relative scientific maturity of knowledge products. This process is described in a 2019 Rand Corporation Report (https://www.rand.org/pubs/research_reports/RR2127.html). The figures below represent a quick reference guide for assessing KRLs for knowledge products.

![Knowledge Readiness Levels Diagram]

**Step 1: Determine the Knowledge Product (KP):**

- **Community Real World**
  - KRL 9
  - KRL 8
  - KRL 7

- **Bedside Applications**
  - KRL 6
  - KRL 5
  - KRL 4

- **Bench Foundations**
  - KRL 3
  - KRL 2
  - KRL 1

KRL 7-9 ratings are given to KPs resulting from research designed to emphasize external validity (generalizability) of knowledge for use in a specified real-world application context. This research often addresses a policy question, asking, “How does it compare to usual practice?” To achieve a rating of KRL 7-9, the KP must be based on valid replicated KRL 4-6 research.

Examples include:
- Battlefield intervention
- Primary care screener
- Workplace prevention
- Systematic reviews of KRL 7-9 research
- Systematic reviews to inform creation of practice guidelines and study of a guideline

KRL 4-6 are given to KPs that seek to generate applied knowledge to eventually perform a non-research related function or to inform understanding of an application or tool. KRL 4-6 research often asks questions such as “Can the application work under ideal research conditions?” and “If the application can work, how does it work?” To achieve a rating of KRL 4-6, the KP must be based on valid, replicated KRL 1-3 research.

Examples include:
- Applications that prevent, screen/diagnose, or treat illness
- Systematic reviews that summarize KRL 4-6 research

KRL 1-3 provide the scientific foundation for KP development toward practical application. These KPs are the outputs of health research that seeks basic mechanisms rather than applications and tends to be theoretical or conceptual, often (but not always) comprising laboratory, descriptive, or exploratory studies.

Examples include:
- Animal research
- Non-clinical laboratory research
- Descriptive epidemiology
- Systematic reviews of KRL 1-3 research
Step 2: Determine the Knowledge Readiness Level (KRL)

KRL1 research replicates or reviews well-designed KRL2 and KRL3 studies (e.g., cost analyses to achieve desired effect; comparative effectiveness studies to aid context specific policy development or intervention decisions; systematic review to estimate effect size with average participants in a real world context; assess “Does the application work?” in a context, or determine for which participants or time period the application works in an identified context.)

KRL2 research expands on or replicates KRL3 studies to directly assess “Does the application work in the context of interest?” It uses valid designs with emphasis on external validity (generalizability) for an intended context (e.g., multisite to obtain average effect; generalizable analyses of real world, e.g., administrative data; usual or standard care (not placebo or contact time) controls; and average (not ideal) participants.)

KRL3 research comprises early studies adapting applications supported by KRL4-6 research for use in a military health context (e.g., adaptation from a longer screener, feasibility and standardization for post-deployment use of a brief screener; initial multi-modal tests of combined KRL4-6 supported interventions to achieve improved outcomes in primary care; adaptation and initial study in military mental health settings of KRL6-8 support therapy for PTSD; adaptation and initial study of KRL6-8 supported protective gear for preventing TBI during deployment.)

KRL4 research replicates well-designed KRL5 studies. It adds nuance to answers from completed studies (e.g., not just “Can it work” and “How, but also “For whom,” “Under what conditions,” or “With what frequency?”) It evaluates hypotheses that may suggest important application contexts (e.g., battlefield, primary care, emergency rooms, post-deployment screening). It includes systematic reviews of KRL5 studies to address “Can it work?” and “How?” questions.

KRL5 research tests a priori (pre-specified) hypotheses using rigorous scientific designs (e.g., RCTs for intervention efficacy) to directly assess “Can it work?” and “If so, how?” It expands on or replicates a KRL4 finding and/or improves on the design of one or more KRL4 studies.

KRL6 research generates initial knowledge regarding a human health-related application or use. KRL4 findings require subsequent replication (e.g., descriptive human epidemiology or preliminary human studies, human studies that test a clinical hypotheses, pilot tests of an intervention, screening or diagnostic tool, and development of instrumentation needed to test an intended application (e.g., outcome measure).

KRL3 research validates hypotheses and hints at future applications, research that replicates or systematically reviews well-designed KRL1-2 studies or theory, descriptive studies, particularly involving animal research (e.g., tool for prediction, prognosis, screening, diagnosis, treatment, prevention).

KRL2 research expands on or replicates a KRL1 finding, including systematic review of KRL1 studies to formulate a theoretical model (e.g., animal studies that test a hypothesis or are the first true experiment on a nascent theory and human studies not based on animal study findings that are descriptive or hypothesis generating.

KRL1 research generates initial or very early scientific knowledge without regard to or indication of a specific health use. Its purpose is inferential, with the intention to generalize. Its findings require replication (e.g., descriptive animal studies, or those that are hypothesis generating rather than hypothesis testing).